cyp3a4 7 Search Results


cyp3a4 7  (Taconic Biosciences)
86
Taconic Biosciences cyp3a4 7
Cyp3a4 7, supplied by Taconic Biosciences, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cyp3a4 7/product/Taconic Biosciences
Average 86 stars, based on 1 article reviews
cyp3a4 7 - by Bioz Stars, 2026-04
86/100 stars
  Buy from Supplier
cyp3a4 7 genes  (Taconic Biosciences)
94
Taconic Biosciences cyp3a4 7 genes
Experimental timeline for nanoformulated drug treatment and blood and tissue collection. NanoATV/r or nanoATV were administered on days 0, 3, 7, 14, and 21 by intramuscular injection to <t>hCYP3A-NOG</t> and NOG mice. Whole blood was collected into heparinized tubes on days 1, 3, 7, 14, 21, and 28 and plasma was prepared. Liver tissue was collected at day 28.
Cyp3a4 7 Genes, supplied by Taconic Biosciences, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cyp3a4 7 genes/product/Taconic Biosciences
Average 94 stars, based on 1 article reviews
cyp3a4 7 genes - by Bioz Stars, 2026-04
94/100 stars
  Buy from Supplier
sheep anti-cyp3a4/7  (Biomol GmbH)
90
Biomol GmbH sheep anti-cyp3a4/7
Experimental timeline for nanoformulated drug treatment and blood and tissue collection. NanoATV/r or nanoATV were administered on days 0, 3, 7, 14, and 21 by intramuscular injection to <t>hCYP3A-NOG</t> and NOG mice. Whole blood was collected into heparinized tubes on days 1, 3, 7, 14, 21, and 28 and plasma was prepared. Liver tissue was collected at day 28.
Sheep Anti Cyp3a4/7, supplied by Biomol GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/sheep anti-cyp3a4/7/product/Biomol GmbH
Average 90 stars, based on 1 article reviews
sheep anti-cyp3a4/7 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
hupxr/car/cyp3a4/7 mouse line  (Hasegawa Co Ltd)
90
Hasegawa Co Ltd hupxr/car/cyp3a4/7 mouse line
Experimental timeline for nanoformulated drug treatment and blood and tissue collection. NanoATV/r or nanoATV were administered on days 0, 3, 7, 14, and 21 by intramuscular injection to <t>hCYP3A-NOG</t> and NOG mice. Whole blood was collected into heparinized tubes on days 1, 3, 7, 14, 21, and 28 and plasma was prepared. Liver tissue was collected at day 28.
Hupxr/Car/Cyp3a4/7 Mouse Line, supplied by Hasegawa Co Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/hupxr/car/cyp3a4/7 mouse line/product/Hasegawa Co Ltd
Average 90 stars, based on 1 article reviews
hupxr/car/cyp3a4/7 mouse line - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
rabbit anti-human polyclonal cyp3a4/7  (Gentest Corp)
90
Gentest Corp rabbit anti-human polyclonal cyp3a4/7
Experimental timeline for nanoformulated drug treatment and blood and tissue collection. NanoATV/r or nanoATV were administered on days 0, 3, 7, 14, and 21 by intramuscular injection to <t>hCYP3A-NOG</t> and NOG mice. Whole blood was collected into heparinized tubes on days 1, 3, 7, 14, 21, and 28 and plasma was prepared. Liver tissue was collected at day 28.
Rabbit Anti Human Polyclonal Cyp3a4/7, supplied by Gentest Corp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rabbit anti-human polyclonal cyp3a4/7/product/Gentest Corp
Average 90 stars, based on 1 article reviews
rabbit anti-human polyclonal cyp3a4/7 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
humanized pxr-car-cyp3a4/3a7 mice  (Taconic Biosciences)
90
Taconic Biosciences humanized pxr-car-cyp3a4/3a7 mice
Experimental timeline for nanoformulated drug treatment and blood and tissue collection. NanoATV/r or nanoATV were administered on days 0, 3, 7, 14, and 21 by intramuscular injection to <t>hCYP3A-NOG</t> and NOG mice. Whole blood was collected into heparinized tubes on days 1, 3, 7, 14, 21, and 28 and plasma was prepared. Liver tissue was collected at day 28.
Humanized Pxr Car Cyp3a4/3a7 Mice, supplied by Taconic Biosciences, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/humanized pxr-car-cyp3a4/3a7 mice/product/Taconic Biosciences
Average 90 stars, based on 1 article reviews
humanized pxr-car-cyp3a4/3a7 mice - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
cyp3a4-7 a234, polyclonal  (Gentest Corp)
90
Gentest Corp cyp3a4-7 a234, polyclonal
Experimental timeline for nanoformulated drug treatment and blood and tissue collection. NanoATV/r or nanoATV were administered on days 0, 3, 7, 14, and 21 by intramuscular injection to <t>hCYP3A-NOG</t> and NOG mice. Whole blood was collected into heparinized tubes on days 1, 3, 7, 14, 21, and 28 and plasma was prepared. Liver tissue was collected at day 28.
Cyp3a4 7 A234, Polyclonal, supplied by Gentest Corp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cyp3a4-7 a234, polyclonal/product/Gentest Corp
Average 90 stars, based on 1 article reviews
cyp3a4-7 a234, polyclonal - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
p450-glo assay containing the cyp3a4/7 substrate (luciferinbe)  (Promega)
90
Promega p450-glo assay containing the cyp3a4/7 substrate (luciferinbe)
Experimental timeline for nanoformulated drug treatment and blood and tissue collection. NanoATV/r or nanoATV were administered on days 0, 3, 7, 14, and 21 by intramuscular injection to <t>hCYP3A-NOG</t> and NOG mice. Whole blood was collected into heparinized tubes on days 1, 3, 7, 14, 21, and 28 and plasma was prepared. Liver tissue was collected at day 28.
P450 Glo Assay Containing The Cyp3a4/7 Substrate (Luciferinbe), supplied by Promega, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/p450-glo assay containing the cyp3a4/7 substrate (luciferinbe)/product/Promega
Average 90 stars, based on 1 article reviews
p450-glo assay containing the cyp3a4/7 substrate (luciferinbe) - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
hupxr/car/cyp3a4/7 model  (Hasegawa Co Ltd)
90
Hasegawa Co Ltd hupxr/car/cyp3a4/7 model
Experimental timeline for nanoformulated drug treatment and blood and tissue collection. NanoATV/r or nanoATV were administered on days 0, 3, 7, 14, and 21 by intramuscular injection to <t>hCYP3A-NOG</t> and NOG mice. Whole blood was collected into heparinized tubes on days 1, 3, 7, 14, 21, and 28 and plasma was prepared. Liver tissue was collected at day 28.
Hupxr/Car/Cyp3a4/7 Model, supplied by Hasegawa Co Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/hupxr/car/cyp3a4/7 model/product/Hasegawa Co Ltd
Average 90 stars, based on 1 article reviews
hupxr/car/cyp3a4/7 model - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

Image Search Results


Experimental timeline for nanoformulated drug treatment and blood and tissue collection. NanoATV/r or nanoATV were administered on days 0, 3, 7, 14, and 21 by intramuscular injection to hCYP3A-NOG and NOG mice. Whole blood was collected into heparinized tubes on days 1, 3, 7, 14, 21, and 28 and plasma was prepared. Liver tissue was collected at day 28.

Journal: The Journal of Pharmacology and Experimental Therapeutics

Article Title: Antiretroviral Drug Metabolism in Humanized PXR-CAR-CYP3A-NOG Mice

doi: 10.1124/jpet.117.247288

Figure Lengend Snippet: Experimental timeline for nanoformulated drug treatment and blood and tissue collection. NanoATV/r or nanoATV were administered on days 0, 3, 7, 14, and 21 by intramuscular injection to hCYP3A-NOG and NOG mice. Whole blood was collected into heparinized tubes on days 1, 3, 7, 14, 21, and 28 and plasma was prepared. Liver tissue was collected at day 28.

Article Snippet: To these ends, we generated a transgenic mouse with targeted replacement of mouse to human PXR, CAR, and CYP3A4/7 genes (Taconic model 11585, or PXR-CAR-CYP3A4/3A7, abbreviated hCYP3A) on a CIEA NOG mouse background.

Techniques: Injection

Drug plasma concentrations in nanoATV or nanoATV/r-treated mice. (A) ATV plasma concentrations in humanized hCYP3A-NOG (hCYP3A) or NOG mice treated intramuscularly with 20 or 50 mg/kg nanoATV/r or 50 mg/kg nanoATV on days 0, 3, 7, 14, and 21. (B) RTV plasma concentrations in hCYP3A and NOG mice treated with 20 or 50 mg/kg nanoATV/r. Data are expressed as mean ± S.E.M. N = 5–8.

Journal: The Journal of Pharmacology and Experimental Therapeutics

Article Title: Antiretroviral Drug Metabolism in Humanized PXR-CAR-CYP3A-NOG Mice

doi: 10.1124/jpet.117.247288

Figure Lengend Snippet: Drug plasma concentrations in nanoATV or nanoATV/r-treated mice. (A) ATV plasma concentrations in humanized hCYP3A-NOG (hCYP3A) or NOG mice treated intramuscularly with 20 or 50 mg/kg nanoATV/r or 50 mg/kg nanoATV on days 0, 3, 7, 14, and 21. (B) RTV plasma concentrations in hCYP3A and NOG mice treated with 20 or 50 mg/kg nanoATV/r. Data are expressed as mean ± S.E.M. N = 5–8.

Article Snippet: To these ends, we generated a transgenic mouse with targeted replacement of mouse to human PXR, CAR, and CYP3A4/7 genes (Taconic model 11585, or PXR-CAR-CYP3A4/3A7, abbreviated hCYP3A) on a CIEA NOG mouse background.

Techniques:

AUC for plasma ATV and RTV Data are expressed as average (ng d/ml) ± S.E.M. Significantly different from NOG mice value: * P < 0.05; **** P < 0.0001. Significantly different from 50 mg/kg nanoATV/r treated mice of similar strain: † P < 0.05; †† P < 0.001.

Journal: The Journal of Pharmacology and Experimental Therapeutics

Article Title: Antiretroviral Drug Metabolism in Humanized PXR-CAR-CYP3A-NOG Mice

doi: 10.1124/jpet.117.247288

Figure Lengend Snippet: AUC for plasma ATV and RTV Data are expressed as average (ng d/ml) ± S.E.M. Significantly different from NOG mice value: * P < 0.05; **** P < 0.0001. Significantly different from 50 mg/kg nanoATV/r treated mice of similar strain: † P < 0.05; †† P < 0.001.

Article Snippet: To these ends, we generated a transgenic mouse with targeted replacement of mouse to human PXR, CAR, and CYP3A4/7 genes (Taconic model 11585, or PXR-CAR-CYP3A4/3A7, abbreviated hCYP3A) on a CIEA NOG mouse background.

Techniques:

Sex-dependent differences in plasma drug concentrations in mice treated with nanoATV/r. ATV (A) and RTV (B) plasma concentrations over time in humanized hCYP3A-NOG (hCYP3A) and NOG male and female mice treated intramuscularly with 50 mg/kg nanoATV/r on days 0, 3, 7, 14, and 21. Data are expressed as mean ± S.E.M. N = 3 (female) or 4 (male).

Journal: The Journal of Pharmacology and Experimental Therapeutics

Article Title: Antiretroviral Drug Metabolism in Humanized PXR-CAR-CYP3A-NOG Mice

doi: 10.1124/jpet.117.247288

Figure Lengend Snippet: Sex-dependent differences in plasma drug concentrations in mice treated with nanoATV/r. ATV (A) and RTV (B) plasma concentrations over time in humanized hCYP3A-NOG (hCYP3A) and NOG male and female mice treated intramuscularly with 50 mg/kg nanoATV/r on days 0, 3, 7, 14, and 21. Data are expressed as mean ± S.E.M. N = 3 (female) or 4 (male).

Article Snippet: To these ends, we generated a transgenic mouse with targeted replacement of mouse to human PXR, CAR, and CYP3A4/7 genes (Taconic model 11585, or PXR-CAR-CYP3A4/3A7, abbreviated hCYP3A) on a CIEA NOG mouse background.

Techniques:

Liver drug concentrations in hCYP3A-NOG (hCYP3A) and NOG mice. Mice were treated intramuscularly with 20 or 50 mg/kg nanoATV/r or 50 mg/kg nanoATV on days 0, 3, 7, 14, and 21 and livers were collected on day 28. Liver ATV (A) and RTV (B) concentrations were determined by UPLC tandem MS. Data are expressed as mean ± S.E.M. *Significantly different than similarly treated NOG mice ( P < 0.05). † Significantly different than hCYP3A mice treated with 50 mg/kg nanoATV/r ( P < 0.05).

Journal: The Journal of Pharmacology and Experimental Therapeutics

Article Title: Antiretroviral Drug Metabolism in Humanized PXR-CAR-CYP3A-NOG Mice

doi: 10.1124/jpet.117.247288

Figure Lengend Snippet: Liver drug concentrations in hCYP3A-NOG (hCYP3A) and NOG mice. Mice were treated intramuscularly with 20 or 50 mg/kg nanoATV/r or 50 mg/kg nanoATV on days 0, 3, 7, 14, and 21 and livers were collected on day 28. Liver ATV (A) and RTV (B) concentrations were determined by UPLC tandem MS. Data are expressed as mean ± S.E.M. *Significantly different than similarly treated NOG mice ( P < 0.05). † Significantly different than hCYP3A mice treated with 50 mg/kg nanoATV/r ( P < 0.05).

Article Snippet: To these ends, we generated a transgenic mouse with targeted replacement of mouse to human PXR, CAR, and CYP3A4/7 genes (Taconic model 11585, or PXR-CAR-CYP3A4/3A7, abbreviated hCYP3A) on a CIEA NOG mouse background.

Techniques:

Liver CYP3A4, PXR, and CAR mRNA levels in mice treated with nanoATV or nanoATV/r. Expression of human and mouse genes for CYP3A4, PXR, and CAR in liver were determined by real-time PCR using human (hCYP3A) and mouse (NOG) specific primers in mice treated with 50 mg/kg nanoATV or 50 mg/kg nanoATV/r. Significant differences were determined by one-tailed Students t test at * P < 0.05; ** P < 0.01. N = 4 to 5 (nanoATV/r-treated males); N = 3 (nanoATV/r-treated females; nanoATV-treated males); N = 2 (nanoATV-treated females).

Journal: The Journal of Pharmacology and Experimental Therapeutics

Article Title: Antiretroviral Drug Metabolism in Humanized PXR-CAR-CYP3A-NOG Mice

doi: 10.1124/jpet.117.247288

Figure Lengend Snippet: Liver CYP3A4, PXR, and CAR mRNA levels in mice treated with nanoATV or nanoATV/r. Expression of human and mouse genes for CYP3A4, PXR, and CAR in liver were determined by real-time PCR using human (hCYP3A) and mouse (NOG) specific primers in mice treated with 50 mg/kg nanoATV or 50 mg/kg nanoATV/r. Significant differences were determined by one-tailed Students t test at * P < 0.05; ** P < 0.01. N = 4 to 5 (nanoATV/r-treated males); N = 3 (nanoATV/r-treated females; nanoATV-treated males); N = 2 (nanoATV-treated females).

Article Snippet: To these ends, we generated a transgenic mouse with targeted replacement of mouse to human PXR, CAR, and CYP3A4/7 genes (Taconic model 11585, or PXR-CAR-CYP3A4/3A7, abbreviated hCYP3A) on a CIEA NOG mouse background.

Techniques: Expressing, Real-time Polymerase Chain Reaction, One-tailed Test